Med-X, Inc. (MXRX)
Med-X was planning to go public, but the IPO was withdrawn on Apr 23, 2024.
IPO Price Range
$4.00 - $6.00
Shares Offered
1,150,000
Deal Size
$5.75M

Company Description

Med-X is currently primarily engaged in the business of supplying environmentally friendly health and wellness products to various industries, including but not limited to the professional pest control industry, over the counter pharmacies through distribution partnerships, as well as directly to consumers.

We strive to be perceived as a health and wellness company offering a series of all-natural and environmentally friendly “green” products and service protocols to other companies and consumers who are also looking to reduce exposure to chemicals and toxins in their personal lives and communities.

Our primary source of revenue is derived from products offered through the following four separate divisions and trade names: Nature-Cide, Thermal-Aid, Malibu Brands and Advertising.

Med-X, Inc.
Country United States
Founded 2014
Industry Health Care
Sector Pharmaceuticals
Employees 16
CEO Matthew Mills

Contact Details

Address:
8236 Remmet Avenue
Canoga Park, CA 91304
United States
Phone (818) 349-2870
Website medx-rx.com

Stock Details

Ticker Symbol MXRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001620704
Employer ID 46-5473113
SIC Code 2834

Key Executives

Name Position
Dr. David E. Toomey Chief Science Officer
Matthew A. Mills Chairman of the Board and Chief Executive Officer
Ronald J. Tchorzewski Director and Chief Financial Officer
Jennifer J. Mills Director, President and Corporate Secretary
Nick Phillips Chief Media Officer
Dr. Morton I. Hyson Director
Dr. Allan Kurtz Director
Fred Dashiell, Jr. Director
Michael Kuntz Director
Dennis Kemmesat Director

Latest SEC Filings

Date Type Title
Dec 18, 2024 1-A/A Filing
Oct 11, 2024 1-A/A Filing
Oct 3, 2024 1-A Filing
Sep 30, 2024 D/A Filing
Sep 27, 2024 C/A Filing
Sep 26, 2024 D Notice of Exempt Offering of Securities
Sep 24, 2024 1-SA Filing
Jul 10, 2024 C/A Filing
Jun 12, 2024 1-K/A Filing
May 28, 2024 C Filing